Depression, Epinephrine, and Platelet Function
NCT00166114 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2015-07-23
Summary
Men and women who have suffered sexual and/or physical abuse before the age of 12 are at increased risk for anxiety and mood disorders, other serious psychiatric disorders, and likely medical illnesses. What is not known is whether adult survivors of childhood adversity experience heightened negative emotions and increased physical responses due to altered norepinephrine or serotonin systems in their brains and bodies. The investigators expect to see that survivors of childhood adversity experience heightened negative emotions and increased physical responses to stress.
Conditions
Interventions
- DRUG
-
Escitalopram
10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
- DRUG
-
Desipramine
25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
Emory University
lead OTHER
Principal Investigators
-
Dominique L Musselman, MD,MS · Emory University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2002-02-28
- Primary Completion
- 2009-01-31
- Completion
- 2009-01-31
Countries
- United States
Study Locations
More Related Trials
-
Identifying Factors That Predict Antidepressant Treatment Response
NCT00360399 ·Status: COMPLETED ·Phase: NA
-
The Effect of SSRIs on Threat of Shock Potentiated Neural Circuitry
NCT07074652 ·Status: COMPLETED ·Phase: NA
-
Serotonin Transporter Genetic Variation and Amygdalar Activation Correlates of Antidepressant Response
NCT00456430 ·Status: COMPLETED ·Phase: PHASE4
-
Advancing Personalized Antidepressant Treatment Using PET/MRI
NCT02623205 ·Status: COMPLETED ·Phase: PHASE4
-
Function of Catecholamines in the Brain During Depression
NCT00082030 ·Status: COMPLETED
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111552 ·Status: TERMINATED ·Phase: PHASE3
-
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01123707 ·Status: TERMINATED ·Phase: PHASE3
-
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
NCT00456014 ·Status: COMPLETED ·Phase: NA
-
Effects Of Antidepressants On Sexual Functioning In Adults
NCT00051272 ·Status: COMPLETED ·Phase: PHASE3
-
Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions
NCT01368432 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
NCT00759395 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
NCT01413932 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder
NCT00000375 ·Status: COMPLETED ·Phase: PHASE4
-
Imaging Predictors of Treatment Response in Depression
NCT00367341 ·Status: COMPLETED ·Phase: NA
-
Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders
NCT03278938 ·Status: WITHDRAWN ·Phase: PHASE4
-
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
NCT00200902 ·Status: COMPLETED ·Phase: PHASE4
-
Escitalopram Treatment In Acute Stroke
NCT01561092 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder
NCT06532604 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders
NCT03294525 ·Status: UNKNOWN
-
This is a Study to Determine the Antidepressant Effects of AZD6765
NCT00986479 ·Status: COMPLETED ·Phase: PHASE2
-
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
NCT05915013 ·Status: RECRUITING ·Phase: PHASE1
-
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
NCT02237937 ·Status: UNKNOWN ·Phase: PHASE4
-
Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression
NCT04234776 ·Status: UNKNOWN ·Phase: PHASE4
-
The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
NCT00107120 ·Status: COMPLETED ·Phase: PHASE3
-
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
NCT05136755 ·Status: RECRUITING ·Phase: PHASE2